What question did this study set out to answer?

Examine how donor type affects post-transplant outcomes in patients with myelodysplastic syndromes receiving anti-thymocyte globulin-based treatment.

April 23, 2026Annals of HematologyOpen Access

Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

Analysis assesses donor type effects on transplant outcomes in myelodysplastic syndrome patients, suggesting notable differences in relapse rates.

Examine how donor type affects post-transplant outcomes in patients with myelodysplastic syndromes receiving anti-thymocyte globulin-based treatment.
Analyzed data from 391 adult patients with myelodysplastic syndromes who underwent allo-HSCT using fludarabine-busulfan and ATG between 2009 and 2019.
Categorized donors into matched sibling donors, unrelated donors, and haploidentical donors, comparing transplant outcomes.
Used multivariate analysis to assess associations between donor type and clinical outcomes.
5-year overall survival was 63.0% and relapse-free survival was 58.4%.
Matched sibling donors had a significantly higher 5-year relapse rate (34.3%) compared to unrelated (16.4%) and haploidentical donors (16.8%), p < 0.001.
MSD was linked to an increased relapse risk and lower incidence of graft-versus-host disease, indicating a possible reduction in graft-versus-leukemia effects.

Park et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis assesses donor type effects on transplant outcomes in myelodysplastic syndrome patients, suggesting notable differences in relapse rates.